Mouse Systems to Model Hepatitis C Virus Treatment and Associated Resistance

While addition of the first-approved protease inhibitors (PIs), telaprevir and boceprevir, to pegylated interferon (PEG-IFN) and ribavirin (RBV) combination therapy significantly increased sustained virologic response (SVR) rates, PI-based triple therapy for the treatment of chronic hepatitis C viru...

Descripción completa

Detalles Bibliográficos
Autores principales: Mesalam, Ahmed Atef, Vercauteren, Koen, Meuleman, Philip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4926196/
https://www.ncbi.nlm.nih.gov/pubmed/27338446
http://dx.doi.org/10.3390/v8060176

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4926196/
https://www.ncbi.nlm.nih.gov/pubmed/27338446
http://dx.doi.org/10.3390/v8060176

Ejemplares similares